Compare Stocks: DTIL, ACRS, CLYM, and DRUG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.78 -1.4%	$5.27	$1.70 ▼ $6.51	$808.18M	0.78	1.87 million shs	666,223 shs
CLYM Climb Bio	$16.33 +10.9%	$12.72	$1.54 ▼ $17.00	$937.93M	0.08	1.04 million shs	2.50 million shs
DRUG Bright Minds Biosciences	$76.44 -2.0%	$70.69	$38.00 ▼ $123.75	$743.93M	-5.27	191,720 shs	151,386 shs
DTIL Precision BioSciences	$7.43 +1.8%	$7.45	$3.53 ▼ $9.62	$205.08M	1.27	271,244 shs	142,104 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-2.20%	+7.84%	+27.88%	+240.00%
CLYM Climb Bio	0.00%	+16.64%	+29.81%	+51.20%	+901.84%
DRUG Bright Minds Biosciences	0.00%	-3.64%	+2.98%	-1.33%	+88.55%
DTIL Precision BioSciences	0.00%	-0.80%	-10.70%	+2.20%	+58.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.78 -1.4%	$5.27	$1.70 ▼ $6.51	$808.18M	0.78	1.87 million shs	666,223 shs
CLYM Climb Bio	$16.33 +10.9%	$12.72	$1.54 ▼ $17.00	$937.93M	0.08	1.04 million shs	2.50 million shs
DRUG Bright Minds Biosciences	$76.44 -2.0%	$70.69	$38.00 ▼ $123.75	$743.93M	-5.27	191,720 shs	151,386 shs
DTIL Precision BioSciences	$7.43 +1.8%	$7.45	$3.53 ▼ $9.62	$205.08M	1.27	271,244 shs	142,104 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-2.20%	+7.84%	+27.88%	+240.00%
CLYM Climb Bio	0.00%	+16.64%	+29.81%	+51.20%	+901.84%
DRUG Bright Minds Biosciences	0.00%	-3.64%	+2.98%	-1.33%	+88.55%
DTIL Precision BioSciences	0.00%	-0.80%	-10.70%	+2.20%	+58.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.13	Buy	$11.50	98.96% Upside
CLYM Climb Bio	3.00	Buy	$22.75	39.31% Upside
DRUG Bright Minds Biosciences	3.14	Buy	$143.83	88.17% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	334.05% Upside

Current Analyst Ratings Breakdown

Latest DTIL, ACRS, CLYM, and DRUG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	CLYM Climb Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $25.00
8/5/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Moderate Buy	$23.00
8/3/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/27/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$17.00 ➝ $20.00
7/21/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	CLYM Climb Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/24/2026	ACRS Aclaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	103.21	N/A	N/A	$0.89 per share	6.49
CLYM Climb Bio	N/A	N/A	N/A	N/A	$4.17 per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
DTIL Precision BioSciences	$34.26M	5.99	N/A	N/A	$1.64 per share	4.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	N/A
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	N/A
DRUG Bright Minds Biosciences	-$8.74M	-$2.08	N/A	N/A	N/A	N/A	-20.58%	-20.25%	N/A
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)

Latest DTIL, ACRS, CLYM, and DRUG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2831	-$0.17	+$1.1131	-$0.17	N/A	N/A
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
5/20/2026	Q2 2026	DRUG Bright Minds Biosciences	-$0.8633	-$0.80	+$0.0633	-$0.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
CLYM Climb Bio	N/A	31.45	31.45
DRUG Bright Minds Biosciences	N/A	81.47	81.47
DTIL Precision BioSciences	0.50	12.82	12.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CLYM Climb Bio	69.76%
DRUG Bright Minds Biosciences	40.52%
DTIL Precision BioSciences	37.99%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
CLYM Climb Bio	2.60%
DRUG Bright Minds Biosciences	42.66%
DTIL Precision BioSciences	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
CLYM Climb Bio	9	57.44 million	55.94 million	N/A
DRUG Bright Minds Biosciences	N/A	9.73 million	5.58 million	Not Optionable
DTIL Precision BioSciences	200	27.60 million	26.86 million	No Data

DTIL, ACRS, CLYM, and DRUG Headlines

Recent News About These Companies

Q3 EPS Estimate for Precision BioSciences Lowered by Analyst

August 16 at 2:01 AM | americanbankingnews.com

What is HC Wainwright's Estimate for DTIL FY2030 Earnings?

August 15 at 2:28 AM | americanbankingnews.com

HC Wainwright Has Bearish Estimate for DTIL Q3 Earnings

August 14 at 8:26 AM | marketbeat.com

HC Wainwright Has Bullish Outlook for DTIL FY2030 Earnings

August 13 at 7:56 AM | marketbeat.com

Precision BioSciences (NASDAQ:DTIL) Announces Quarterly Earnings Results

August 8, 2026 | marketbeat.com

Precision BioSciences (NASDAQ:DTIL) Cut to Sell at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Precision BioSciences (NASDAQ:DTIL) Lowered to "Sell" Rating by Wall Street Zen

August 8, 2026 | marketbeat.com

Precision BioSciences: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | businesswire.com

FY2030 Earnings Forecast for DTIL Issued By HC Wainwright

August 6, 2026 | americanbankingnews.com

Q2 EPS Forecast for Precision BioSciences Lowered by Analyst

August 5, 2026 | marketbeat.com

Precision BioSciences (DTIL) to Post Earnings on Thursday

August 5, 2026 | americanbankingnews.com

HC Wainwright Reiterates "Buy" Rating for Precision BioSciences (NASDAQ:DTIL)

August 5, 2026 | americanbankingnews.com

What is HC Wainwright's Forecast for DTIL FY2030 Earnings?

August 4, 2026 | marketbeat.com

Precision BioSciences (NASDAQ:DTIL) Earns "Buy" Rating from HC Wainwright

August 3, 2026 | marketbeat.com

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

July 31, 2026 | businesswire.com

Precision BioSciences (DTIL) Expected to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Precision BioSciences, Inc. (NASDAQ:DTIL) Given Consensus Rating of "Moderate Buy" by Analysts

July 29, 2026 | marketbeat.com

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

July 27, 2026 | businesswire.com

Octagon Capital Advisors LP Acquires 318,737 Shares of Precision BioSciences, Inc. $DTIL

July 27, 2026 | marketbeat.com

Affinity Asset Advisors LLC Purchases Shares of 597,946 Precision BioSciences, Inc. $DTIL

July 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, ACRS, CLYM, and DRUG Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$5.78 -0.08 (-1.37%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.82 +0.04 (+0.69%)

As of 08/14/2026 07:34 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Climb Bio NASDAQ:CLYM

$16.33 +1.60 (+10.86%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$16.65 +0.32 (+1.96%)

As of 08/14/2026 07:37 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Bright Minds Biosciences NASDAQ:DRUG

$76.44 -1.56 (-2.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.25 -0.19 (-0.25%)

As of 08/14/2026 07:34 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Precision BioSciences NASDAQ:DTIL

$7.43 +0.13 (+1.78%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$7.44 +0.02 (+0.20%)

As of 08/14/2026 07:34 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, ACRS, CLYM, and DRUG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, ACRS, CLYM, and DRUG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, ACRS, CLYM, and DRUG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, ACRS, CLYM, and DRUG Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Climb Bio NASDAQ:CLYM

Bright Minds Biosciences NASDAQ:DRUG

Precision BioSciences NASDAQ:DTIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, ACRS, CLYM, and DRUG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, ACRS, CLYM, and DRUG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, ACRS, CLYM, and DRUG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, ACRS, CLYM, and DRUG Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Climb Bio NASDAQ:CLYM

Bright Minds Biosciences NASDAQ:DRUG

Precision BioSciences NASDAQ:DTIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools